Making More Effective Antibody-Based Immunotherapies with the GS Effex® Cell Line

Antibody-based immunotherapies can mediate cancer cell death via multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). The level of ADCC activity has been shown to have a direct impact on their potency. One of the most effective means of increasing ADCC activity is to eliminate fucose residues within the Fc region of the antibodies. GS Effex®, derived from Lonza’s leading GS Xceed® cell line, has been engineered to produce antibodies free of fucose residues in the Fc region without compromising on cell growth, titers, or product quality.